Literature DB >> 1279812

Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy.

A Gaur1, B Wiers, A Liu, J Rothbard, C G Fathman.   

Abstract

Experimental autoimmune encephalomyelitis (EAE), a demyelinating disease of the central nervous system that can be induced in susceptible strains of mice by immunization with myelin basic protein (MBP) or its immunodominant T cell determinants, serves as a model of human multiple sclerosis. Tolerance to MBP in adult mice was induced by intraperitoneal injection of synthetic peptides of immunodominant determinants of MBP and prevented MBP-induced EAE. Furthermore, tolerance-inducing regimens of peptides administered to mice after the disease had begun (10 days after induction with MBP) blocked the progression and decreased the severity of EAE. Peptide-induced tolerance resulted from the induction of anergy in proliferative, antigen-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279812     DOI: 10.1126/science.1279812

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  50 in total

Review 1.  T-cell regulation of peripheral tolerance and immunity: the potential role for Notch signalling.

Authors:  G F Hoyne; M J Dallman; J R Lamb
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

2.  Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope.

Authors:  M Stienekemeier; K Falk; O Rötzschke; A Weishaupt; C Schneider; K V Toyka; R Gold; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

Review 3.  Inhibition of human T-cell responses by allergen peptides.

Authors:  M Larché
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 4.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

5.  Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.

Authors:  F Bischof; W Wienhold; C Wirblich; G Malcherek; O Zevering; A M Kruisbeek; A Melms
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.

Authors:  K W Wucherpfennig; I Catz; S Hausmann; J L Strominger; L Steinman; K G Warren
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 7.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

8.  The solution structure of the N-terminal domain of alpha2-macroglobulin receptor-associated protein.

Authors:  P R Nielsen; L Ellgaard; M Etzerodt; H C Thogersen; F M Poulsen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

9.  Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.

Authors:  P Aichele; D Kyburz; P S Ohashi; B Odermatt; R M Zinkernagel; H Hengartner; H Pircher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

10.  Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop.

Authors:  J Bergquist; A Tarkowski; R Ekman; A Ewing
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.